There is no way to identify patients who will harbor small volume, unilateral prostate cancer at final pathology. Implications for focal therapies

Alberto Briganti, Manuela Tutolo, Nazareno Suardi, Andrea Gallina, Firas Abdollah, Umberto Capitanio, Massimo Freschi, Marco Bianchi, Andrea Salonia, Renzo Colombo, Patrizio Rigatti, Francesco Montorsi

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background The aim of this study was to assess the clinical characteristics of the potentially ideal candidates for focal therapy, that is, patients with unilateral, small volume (namely, pT2a) prostate cancer (PCa) at radical prostatectomy (RP). MATERIALS AND Methods We evaluated 2,503 consecutive pT2 PCa patients treated with RP between 2002 and 2009 at a single center. Within this population, the clinical characteristics of patients with pT2a and pT2b/c disease were compared. Univariable and multivariable logistic regression models were fitted to assess clinical predictors of pT2a at RP. Results Overall, 349 patients (14%) had pT2a PCa, while the remaining patients had either pT2b (n = 334; 15.5%) or pT2c disease (n = 1,820 patients; 84.5%). Patients with pT2a PCa had a significantly lower mean PSA value, lower mean percentage of positive biopsy cores and lower biopsy Gleason score distribution (all P â0.03). However, at multivariable analyses, only percentage of positive cores maintained an independent predictor status (Pâ0.01). Even when considering only patients sharing all the most favorable PCa characteristics (namely, clinical stage T1, PS≤4, Gleason score â6 and percentage of positive cores a;circ25%), the rate of pT2a disease was only 24%. Conclusions The rate of small volume, unilateral PCa even among patients with extremely favourable PCa characteristics was remarkably low (roughly 25%). This suggests that: (1) Three quarters of the best candidates for focal therapy would ultimately show adverse pathological features; (2) At present, accurate identification of the ideal candidate for focal therapy is not possible with current clinical-pathologic parameters.

Original languageEnglish
Pages (from-to)925-930
Number of pages6
JournalProstate
Volume72
Issue number8
DOIs
Publication statusPublished - Jun 1 2012

Fingerprint

Prostatic Neoplasms
Pathology
Prostatectomy
Therapeutics
Neoplasm Grading
Logistic Models
Biopsy
Population

Keywords

  • focal therapy
  • prostate cancer
  • pT2a
  • unilateral

ASJC Scopus subject areas

  • Urology
  • Oncology

Cite this

There is no way to identify patients who will harbor small volume, unilateral prostate cancer at final pathology. Implications for focal therapies. / Briganti, Alberto; Tutolo, Manuela; Suardi, Nazareno; Gallina, Andrea; Abdollah, Firas; Capitanio, Umberto; Freschi, Massimo; Bianchi, Marco; Salonia, Andrea; Colombo, Renzo; Rigatti, Patrizio; Montorsi, Francesco.

In: Prostate, Vol. 72, No. 8, 01.06.2012, p. 925-930.

Research output: Contribution to journalArticle

@article{b5bd7be8c0ea4fb5a57abe709e7742a3,
title = "There is no way to identify patients who will harbor small volume, unilateral prostate cancer at final pathology. Implications for focal therapies",
abstract = "Background The aim of this study was to assess the clinical characteristics of the potentially ideal candidates for focal therapy, that is, patients with unilateral, small volume (namely, pT2a) prostate cancer (PCa) at radical prostatectomy (RP). MATERIALS AND Methods We evaluated 2,503 consecutive pT2 PCa patients treated with RP between 2002 and 2009 at a single center. Within this population, the clinical characteristics of patients with pT2a and pT2b/c disease were compared. Univariable and multivariable logistic regression models were fitted to assess clinical predictors of pT2a at RP. Results Overall, 349 patients (14{\%}) had pT2a PCa, while the remaining patients had either pT2b (n = 334; 15.5{\%}) or pT2c disease (n = 1,820 patients; 84.5{\%}). Patients with pT2a PCa had a significantly lower mean PSA value, lower mean percentage of positive biopsy cores and lower biopsy Gleason score distribution (all P {\^a}0.03). However, at multivariable analyses, only percentage of positive cores maintained an independent predictor status (P{\^a}0.01). Even when considering only patients sharing all the most favorable PCa characteristics (namely, clinical stage T1, PS≤4, Gleason score {\^a}6 and percentage of positive cores a;circ25{\%}), the rate of pT2a disease was only 24{\%}. Conclusions The rate of small volume, unilateral PCa even among patients with extremely favourable PCa characteristics was remarkably low (roughly 25{\%}). This suggests that: (1) Three quarters of the best candidates for focal therapy would ultimately show adverse pathological features; (2) At present, accurate identification of the ideal candidate for focal therapy is not possible with current clinical-pathologic parameters.",
keywords = "focal therapy, prostate cancer, pT2a, unilateral",
author = "Alberto Briganti and Manuela Tutolo and Nazareno Suardi and Andrea Gallina and Firas Abdollah and Umberto Capitanio and Massimo Freschi and Marco Bianchi and Andrea Salonia and Renzo Colombo and Patrizio Rigatti and Francesco Montorsi",
year = "2012",
month = "6",
day = "1",
doi = "10.1002/pros.21497",
language = "English",
volume = "72",
pages = "925--930",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "8",

}

TY - JOUR

T1 - There is no way to identify patients who will harbor small volume, unilateral prostate cancer at final pathology. Implications for focal therapies

AU - Briganti, Alberto

AU - Tutolo, Manuela

AU - Suardi, Nazareno

AU - Gallina, Andrea

AU - Abdollah, Firas

AU - Capitanio, Umberto

AU - Freschi, Massimo

AU - Bianchi, Marco

AU - Salonia, Andrea

AU - Colombo, Renzo

AU - Rigatti, Patrizio

AU - Montorsi, Francesco

PY - 2012/6/1

Y1 - 2012/6/1

N2 - Background The aim of this study was to assess the clinical characteristics of the potentially ideal candidates for focal therapy, that is, patients with unilateral, small volume (namely, pT2a) prostate cancer (PCa) at radical prostatectomy (RP). MATERIALS AND Methods We evaluated 2,503 consecutive pT2 PCa patients treated with RP between 2002 and 2009 at a single center. Within this population, the clinical characteristics of patients with pT2a and pT2b/c disease were compared. Univariable and multivariable logistic regression models were fitted to assess clinical predictors of pT2a at RP. Results Overall, 349 patients (14%) had pT2a PCa, while the remaining patients had either pT2b (n = 334; 15.5%) or pT2c disease (n = 1,820 patients; 84.5%). Patients with pT2a PCa had a significantly lower mean PSA value, lower mean percentage of positive biopsy cores and lower biopsy Gleason score distribution (all P â0.03). However, at multivariable analyses, only percentage of positive cores maintained an independent predictor status (Pâ0.01). Even when considering only patients sharing all the most favorable PCa characteristics (namely, clinical stage T1, PS≤4, Gleason score â6 and percentage of positive cores a;circ25%), the rate of pT2a disease was only 24%. Conclusions The rate of small volume, unilateral PCa even among patients with extremely favourable PCa characteristics was remarkably low (roughly 25%). This suggests that: (1) Three quarters of the best candidates for focal therapy would ultimately show adverse pathological features; (2) At present, accurate identification of the ideal candidate for focal therapy is not possible with current clinical-pathologic parameters.

AB - Background The aim of this study was to assess the clinical characteristics of the potentially ideal candidates for focal therapy, that is, patients with unilateral, small volume (namely, pT2a) prostate cancer (PCa) at radical prostatectomy (RP). MATERIALS AND Methods We evaluated 2,503 consecutive pT2 PCa patients treated with RP between 2002 and 2009 at a single center. Within this population, the clinical characteristics of patients with pT2a and pT2b/c disease were compared. Univariable and multivariable logistic regression models were fitted to assess clinical predictors of pT2a at RP. Results Overall, 349 patients (14%) had pT2a PCa, while the remaining patients had either pT2b (n = 334; 15.5%) or pT2c disease (n = 1,820 patients; 84.5%). Patients with pT2a PCa had a significantly lower mean PSA value, lower mean percentage of positive biopsy cores and lower biopsy Gleason score distribution (all P â0.03). However, at multivariable analyses, only percentage of positive cores maintained an independent predictor status (Pâ0.01). Even when considering only patients sharing all the most favorable PCa characteristics (namely, clinical stage T1, PS≤4, Gleason score â6 and percentage of positive cores a;circ25%), the rate of pT2a disease was only 24%. Conclusions The rate of small volume, unilateral PCa even among patients with extremely favourable PCa characteristics was remarkably low (roughly 25%). This suggests that: (1) Three quarters of the best candidates for focal therapy would ultimately show adverse pathological features; (2) At present, accurate identification of the ideal candidate for focal therapy is not possible with current clinical-pathologic parameters.

KW - focal therapy

KW - prostate cancer

KW - pT2a

KW - unilateral

UR - http://www.scopus.com/inward/record.url?scp=84860335162&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860335162&partnerID=8YFLogxK

U2 - 10.1002/pros.21497

DO - 10.1002/pros.21497

M3 - Article

C2 - 21965006

AN - SCOPUS:84860335162

VL - 72

SP - 925

EP - 930

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 8

ER -